– FRANCE, Paris / USA, NY – Rarecells, Inc. today announced the appointment of Dr. Neil Gunn to its Board as an Independent Director.
“We are delighted to welcome Neil as Board Director. With his broad understanding of diagnostics and the Liquid Biopsy space he is well-positioned to provide valuable perspectives and insight across a broad spectrum of topics, from strategic development to operational expertise and go-to-market potential for our products” said Chairman and CEO, Pr. Patrizia Paterlini-Bréchot.
Davide Bréchot,’ Deputy CEO and Secretary added, “Neil will bring important experience to our Board, from strategic opportunities to business management, leadership, operations, and sustainability. His nomination exemplifies Rarecells’ commitment to best-in-class corporate governance. We look forward to his contribution to our Board.”
About Dr. Neil Gunn
Dr. Neil Gunn has recognized management experience in large and small company settings and within liquid biopsy, sequencing, assay development, and go-to-market strategies. He has served as CEO at IDbyDNA, a metagenomics company acquired by Illumina in June of 2022. Dr. Gunn was the Head of Global Business at Roche Molecular Systems for 7 years followed by the position of President and Head of Roche Sequencing for 5 years.
Dr. Neil Gunn commented “I’m thrilled to be joining the Board of Directors at Rarecells, a highly innovative company in the field of liquid biopsy where such disruptive molecular products will shape the future of predictive oncology. I look forward to contributing to the company’s growth, strategic positioning, and journey.”
About Rarecells Inc.
Rarecells Inc. is a leading company in developing innovative non-invasive tests for very Early Cancer Diagnosis based on proprietary hypersensitive AI-based Circulating Tumor Cells and CTC-DNA detection. Founded in 2012, the firm is headquartered in New York and maintains offices and laboratories in New York and Paris.
For more information: https://www.rarecells.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
